Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Biotech M&A: will the 2018 surge last?

Analysts are predicting a surge of M&A activity in the biotech space, with large pharma firms looking to pad their pipelines with new acquisitions, US tax reform freeing up cash flow, and rapidly-consolidating US healthcare buyers likely to put more pressure on the price of existing drugs. How is the biotech M&A landscape likely to develop over the course of 2018?

Go Top